Related Experiment Video

Updated: May 29, 2026

Amplitude-Integrated EEG in Infants at Risk of Hypoxic-Ischemic Encephalopathy: A Feasibility Study in Road and Air Transport in Western Australia
05:15

Amplitude-Integrated EEG in Infants at Risk of Hypoxic-Ischemic Encephalopathy: A Feasibility Study in Road and Air Transport in Western Australia

Published on: June 21, 2024

Is it time to commence newborn screening for congenital adrenal hyperplasia in Australia?

Joyce Y Wu1, Sudeep, David M Cowley

  • 1Department of Clinical Chemistry, Mater Hospital, Brisbane, QLD, Australia. joyce.wu@mater.org.au

The Medical Journal of Australia
|September 8, 2011
PubMed

Insights

21-Hydroxylase deficiency (21-OHD) is a common cause of congenital adrenal hyperplasia. Implementing newborn screening for 21-OHD in Australia can effectively reduce infant morbidity and mortality.

Area of Science:

  • Endocrinology
  • Genetics
  • Neonatal Medicine

Background:

  • 21-Hydroxylase deficiency (21-OHD) is the leading cause of congenital adrenal hyperplasia, affecting 1 in 14,000 live births.
  • The severe salt-wasting form of 21-OHD poses significant risks of life-threatening crises in newborns.
  • Despite recommendations, 21-OHD newborn screening is not standard in Australia.

Observation:

  • A case report highlights the critical need for 21-OHD newborn screening.
  • Current newborn screening protocols do not include 21-OHD in Australia.

Findings:

  • 21-OHD newborn screening (NBS) is a reliable, sensitive, and effective method.
  • NBS for 21-OHD demonstrably reduces infant morbidity and mortality.

Implications:

  • Implementing 21-OHD NBS in Australia is crucial for preventing severe health outcomes.
  • Expanding newborn screening programs can improve infant health and survival rates.
  • This case underscores the importance of policy review for national newborn screening.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...